Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis

Journal of Cellular Biochemistry

Volumn 85, Issue 4, 2002, Pages 670-677

  Sheard, Michael A ^a   Vojtesek, Borek ^a   Simickova, Marta ^a   Valik, Dalibor ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Breast cancer; Caspase; CD95 Fas; Proliferation; Tumor marker

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; CYTOKERATIN 18; CYTOKERATIN 19; DNA FRAGMENT; FAS ANTIGEN; LIPOCORTIN 5; MITOMYCIN C; PROPIDIUM IODIDE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN SECRETION;

ANTIGENS, NEOPLASM; APOPTOSIS; BREAST NEOPLASMS; CASPASES; EXTRACELLULAR SPACE; FEMALE; HUMANS; KERATINS; PEPTIDE FRAGMENTS; PEPTIDES; SOLUBILITY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0036242519     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10173     Document Type: Article

References (28)

1. Expression of monoclonal antibody- defined epitopes of keratin 19 in human tumours and cultured cells
2. A series of 14 new monoclonal antibodies to keratins: Characterization and value in diagnostic histopathology
3. Cell death in health and disease: The biology and regulation of apoptosis
4. Lung cancer-associated keratin 19 fragments: Development and biochemical characterisation of the new serum assay Enzymun-Test CYFRA 21-1
5. Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments
6. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis
7. Elevated serum and BAL cytokeratin 19 fragment in pulmonary fibrosis and acute interstitialpneumonia
8. The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines
9. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease
10. Elevation of cytokeratin 19 fragment in patients with interstitial pneumonia associated with polymyositis/ dermatomyositis
11. Increased serum tissue polypeptide specific antigen (TPS) in alcoholics: A possible marker of alcoholic hepatitis
12. Apoptotic pathways: Paper wraps stone blunts scissors
13. Tissue polypeptide specific antigen in hepatitis B carriers
14. Novel monoclonal antibodies defining epitope of human cytokeratin 18 molecule
15. Immunocytochemical detection and mapping of a cytokeratin 18 neoepitope exposed during early apoptosis
16. Active caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in TRAIL-induced apoptosis
17. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma
18. Evaluation of tissue polypeptide specific antigen CYFRA 21-1 and carcinoembryonic antigen in nonsmall cell lung carcinoma: Does the combined use of cytokeratin markers give any additional information?
19. Clinical utility of TPS, TPA, and CA 19-9 measurement in pancreatic cancer
20. Diagnostic value of tissue polypeptidespecific antigen (TPS) in neuroblastoma and Wilms' tumour
21. Building better vaccines: How apoptotic cell death can induce inflammation and activate innate and adaptive immunity
22. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18
23. Fractionated gamma-irradiation renders tumour cells more responsive to apoptotic signals through CD95
24. Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients
25. Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy
26. Serum tissue polypeptidespecific antigen (TPS): What is its diagnostic value?
27. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer